AREG and cancer: Thus, Amphiregulin participates in cancer cell proliferation, migration, invasion, and angiogenesis in human carcinomas (Ma et al., 2001), so Amphiregulin was incriminated as a predictive biomarker of anti-EGFR therapy for most EGFR-driven carcinomas (Zarkavelis et al., 2017).